Amarin Corporation plc (AMRN)
-NasdaqGM 6.52 
0.08(1.21%) 3:26PM EDT - Nasdaq Real Time Price
| Prev Close: | 6.60 |
|---|
| Open: | 6.67 |
|---|
| Bid: | 6.54 x 1900 |
|---|
| Ask: | 6.55 x 2300 |
|---|
| 1y Target Est: | 18.56 |
|---|
| Beta: | 1.26 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 6.49 - 6.68 |
|---|
| 52wk Range: | 6.25 - 15.96 |
|---|
| Volume: | 3,084,015 |
|---|
| Avg Vol (3m): | 3,760,700 |
|---|
| Market Cap: | 982.45M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Is ANCHOR Do Or Die For Amarin?at Seeking Alpha(Wed 2:24PM EDT)
- Amarin: FDA Panel Date, Misplaced Hype For Fixed-Dose Comboat TheStreet(Wed 11:22AM EDT)
- InPlay: Amarin Informed by FDA of Oct 16th Advisory Committee Date in Connection With Supplemental New Drug Application for Vascepa in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed DyslipidemiaBriefing.com(Wed 7:59AM EDT)
- Amarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed DyslipidemGlobeNewswire(Wed 7:59AM EDT)
- AMARIN CORP PLC\UK Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed 1:04AM EDT)
- Amarin: Mr. NCE Guy Has Left The Buildingat Seeking Alpha(Sun, Jun 16)
- AstraZeneca's Buying Spree Bolsters Pipelineat Motley Fool(Sat, Jun 15)
- Amarin Investors Should Avoid The Bullish Speculationat Seeking Alpha(Wed, Jun 12)
- Bull, Bear, Or Indifferent: Profiting From Amarin's Latestat Seeking Alpha(Tue, Jun 11)
- A Winning Biotechnology Betat Motley Fool(Mon, Jun 10)
- Largest option buying in equities so faroptionMONSTER(Mon, Jun 10)
- Amarin Investors Should Avoid The Bear Trapsat Seeking Alpha(Mon, Jun 10)
- AstraZeneca’s Acquisition of Omthera Pharma Is a Desperate Actat Motley Fool(Sat, Jun 8)
- Avandia Vote Ends An Era Of Drug Safety Scandalsat Forbes(Thu, Jun 6)
- As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panelat TheStreet(Thu, Jun 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 424.82 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.45 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.06 |
|---|
Business Summary
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases.
View More